New hope for women with Hard-to-Treat ovarian cancer
NCT ID NCT05465941
Summary
This study is testing if a new drug called PLX038 can shrink tumors in people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The drug works by blocking enzymes that cancer cells need to grow. Researchers will give the drug through an IV every three weeks and closely monitor if tumors shrink and how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.